Novo Nordisk Launches Wegovy Pill to Challenge Eli Lilly

Novo Nordisk launched a pill version of its weight-loss drug Wegovy to compete for dominance in the GLP-1 market. The company reported that the oral formulation represents the "strongest US GLP-1 volume launch to-date," indicating higher early demand than the competing offering from Eli Lilly and Company.

While Eli Lilly previously led the injectable market with Mounjaro and Zepbound, it has introduced a new formulation called Foundayo for its pill version. Novo Nordisk is leveraging the established Wegovy brand to gain ground and seeks a market valuation more aligned with the price-to-earnings ratio of Eli Lilly.

To ensure the success of this rollout, Novo Nordisk is prioritizing production capacity to avoid the manufacturing failures that hindered the initial launch of its injectable products.